1485P - Localized undifferentiated endometrial sarcomas (LUES): results of a French Sarcoma Group (FSG) retrospective series of 39 patients (pts)

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Gynaecologic Malignancies
Presenter Marie Meurer
Citation Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387
Authors M. Meurer1, F. Duffaud2, S. Salas2, F. Bertucci3, A. Floquet4, N. Penel5, I. Ray-Coquard6, A. Italiano7, J. Blay8, P. Pautier9, M. Delannes10, S. Piperno-Neumann11, J. Mancini1, M. Auriche9
  • 113, CHU La Timone Adultes, 13085 - Marseille/FR
  • 2Oncology, CHU La Timone Adultes, 13385 - Marseille/FR
  • 313, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 4Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 5Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 6Medical Oncology, Centre Léon Bérard, Lyon/FR
  • 7Medicine, Institute Bergonié, 33076 - Bordeaux/FR
  • 8Medical Oncology, Centre Leon Berard, 69008 - Lyon/FR
  • 9Medical Oncology, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 1031, IUCT, 3100 - Toulouse/FR
  • 11Medical Oncology, Institut Curie, 75248 cedex5 - Paris/FR



UES are tumors of very bad prognosis. Although large surgical resection is the cornerstone of curative intent treatment, the optimal post-operative strategy remains unclear.


We conducted a retrospective analysis of LUES pts (Stade I-III) over the last 8 years in 10 FSG centers, from Netsarc and RRePs databases.


Thirty-nine pts with primary LUES treated from 2008 to 2016 were included, with median age of 61 years (range, 43-80), and median ECOG of 0 (range, 0-3). Metrorrhagia, abdominal pain, and pelvic mass bleeding were the most common symptoms. The locoregional extension report usually included: gynecological examination (71%), and/or pelvic MRI (83%) and/or abdomino-pelvic CT scan (43%). The remote extension report was performed preoperatively for only 17/39 (50%) pts. Among 39 LUES, 24 (67%) were stage I, 3 (8%) stage II and 9 (25%) stage III. All the patients were operated on and surgical procedures were radical hysterectomy and bilateral oophorectomy for 26/39 (70%).Tumor resections were mostly R0, 23/39 (74%) and R1, 6/39 (19%). Tumor rupture occurred in 6 pts. For 7/39 LUES there was a positivity of hormonal receptors and/or cyclin D1. Twenty-two (56%) received post-operative radiotherapy (11 of them with complementary brachytherapy) and 11 (31%) adjuvant chemotherapy. With a median follow-up of 33 months (0.3-112), 17/39 pts are alive, 21/39 (54%) relapsed (7 local relapse and 13 metastases). The 3- and 5-year Overall Survival (OS) rates are 49.8% and 31.1% respectively. Median OS and Relapse-Free Survival (RFS) are 32.7 (16.3-49.1) and 23 (4.4-41.6) months, respectively. In univariate analysis; early FIGO stage (p 


Treatment of primary LUES is radical hysterectomy and bilateral oophorectomy. Adjuvant radiotherapy appears beneficial for RFS and OS. The FIGO stage seems to have an impact on OS. A prospective study could be carried out to validate this therapeutic management.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.